Sarepta Therapeutics surges 36% after-hours following expanded FDA approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Baird on Sarepta (SRPT): 'we think the regulatory progress can generate incremental optimism around the valuation'
June 24, 2024 12:18 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Incrementally positive on regulatory submission. This morning, partner Roche (RHHBY, not covered) announced that EMA has validated and initiated review of the... More
Sarepta Therapeutics (SRPT) PT Raised to $200 at Mizuho
June 24, 2024 5:33 AM EDTMizuho analyst Uy Ear raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $200.00 (from $179.00) while maintaining a Buy rating.
The analyst comments "Following Thursday's Elevidys label expansion, we maintain our Outperform rating on SRPT due to: (1) Potential upside to LT Consensus Elevidys... More
Citi Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
June 21, 2024 5:49 AM EDTCiti analyst Neena Bitritto-Garg reiterated a Buy rating and $172.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "After market close on Thursday, June 20, SRPT announced that the FDA has granted traditional (full) approval to Elevidys for ambulatory DMD patients and accelerated... More
Sarepta Therapeutics (SRPT) PT Raised to $213 at BofA Securities
June 21, 2024 5:36 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $166.00) while maintaining a Buy rating.
The analyst comments "Elevidys received full approval for ambulatory Duchenne muscular dystrophy (DMD) patients ages 4 or more and accelerated approval... More
Goldman Sachs Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
June 21, 2024 5:25 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $223.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "The FDA broadened the label for SRPT's gene therapy Elevidys in Duchenne muscular dystrophy from the accelerated approval in ambulatory 4-5 year-olds to include ambulatory and non-ambulatory patients at least four years old via traditional... More
Sarepta Therapeutics (SRPT) PT Raised to $182 at RBC Capital
June 21, 2024 4:50 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $182.00 (from $142.00) while maintaining a Sector Perform rating.
The analyst comments "Despite our concerns going in that CBER head Peter Marks' tone had shifted and that the... More
